BDBM253920 US9464092, L::US9527857, L

SMILES CC(C)N1CCN(C[C@H]1C)c1ccc(Nc2ncc3cc4C(=O)NCC5(CCCCC5)n4c3n2)nc1

InChI Key InChIKey=OPZYOZIXBOTMIQ-UHFFFAOYSA-N

Data  9 IC50

  Tab Delimited (TSV)   2D SDfile   Computed 3D by Vconf -m prep SDfile
Find this compound or compounds like it in BindingDB:
   Substructure
Similarity at least:  must be >=0.5
Exact match

Activity Spreadsheet -- Enzyme Inhibition Constant Data from BindingDB

Found 9 hits for monomerid = 253920   

TargetCyclin-dependent kinase 4/G1/S-specific cyclin-D1(Human)
Gi Therapeutics

US Patent
LigandPNGBDBM253920(US9464092, L | US9527857, L)
Affinity DataIC50: 5.70nMAssay Description:Selected compounds disclosed herein were tested in CDK4/cyclinD1, CDK2/CycA and CDK2/cyclinE kinase assays by Nanosyn (Santa Clara, Calif.) to determ...More data for this Ligand-Target Pair
In Depth
Date in BDB:
8/25/2018
Entry Details
US Patent

TargetCyclin-dependent kinase 2/G1/S-specific cyclin-E1(Human)
Gi Therapeutics

US Patent
LigandPNGBDBM253920(US9464092, L | US9527857, L)
Affinity DataIC50: 4.53E+3nMAssay Description:Selected compounds disclosed herein were tested in CDK4/cyclinD1, CDK2/CycA and CDK2/cyclinE kinase assays by Nanosyn (Santa Clara, Calif.) to determ...More data for this Ligand-Target Pair
In Depth
Date in BDB:
8/25/2018
Entry Details
US Patent

TargetCyclin-A2/Cyclin-dependent kinase 2(Human)
Gi Therapeutics

US Patent
LigandPNGBDBM253920(US9464092, L | US9527857, L)
Affinity DataIC50: 1.49E+3nMAssay Description:Selected compounds disclosed herein were tested in CDK4/cyclinD1, CDK2/CycA and CDK2/cyclinE kinase assays by Nanosyn (Santa Clara, Calif.) to determ...More data for this Ligand-Target Pair
In Depth
Date in BDB:
8/25/2018
Entry Details
US Patent

TargetCyclin-dependent kinase 4/G1/S-specific cyclin-D1(Human)
Gi Therapeutics

US Patent
LigandPNGBDBM253920(US9464092, L | US9527857, L)
Affinity DataIC50: 5.70nMAssay Description:Selected compounds disclosed herein were tested in CDK4/cyclinD1, CDK6/CycD3 CDK2/CycA and CDK2/cyclinE kinase assays by Nanosyn (Santa Clara, Calif....More data for this Ligand-Target Pair
In Depth
Date in BDB:
10/9/2017
Entry Details
US Patent

TargetCyclin-dependent kinase 2/G1/S-specific cyclin-E1(Human)
Gi Therapeutics

US Patent
LigandPNGBDBM253920(US9464092, L | US9527857, L)
Affinity DataIC50: 4.53E+3nMAssay Description:Selected compounds disclosed herein were tested in CDK4/cyclinD1, CDK6/CycD3 CDK2/CycA and CDK2/cyclinE kinase assays by Nanosyn (Santa Clara, Calif....More data for this Ligand-Target Pair
In Depth
Date in BDB:
10/9/2017
Entry Details
US Patent

TargetCyclin-A2/Cyclin-dependent kinase 2(Human)
Gi Therapeutics

US Patent
LigandPNGBDBM253920(US9464092, L | US9527857, L)
Affinity DataIC50: 1.49E+3nMAssay Description:Selected compounds disclosed herein were tested in CDK4/cyclinD1, CDK6/CycD3 CDK2/CycA and CDK2/cyclinE kinase assays by Nanosyn (Santa Clara, Calif....More data for this Ligand-Target Pair
In Depth
Date in BDB:
10/9/2017
Entry Details
US Patent

TargetCyclin-dependent kinase 4/G1/S-specific cyclin-D1(Human)
Gi Therapeutics

US Patent
LigandPNGBDBM253920(US9464092, L | US9527857, L)
Affinity DataIC50: 5.70nMAssay Description:Selected compounds disclosed herein were tested in CDK4/cyclinD1, CDK2/CycA and CDK2/cyclinE kinase assays by Nanosyn (Santa Clara, Calif.) to determ...More data for this Ligand-Target Pair
In Depth
Date in BDB:
12/4/2017
Entry Details
US Patent

TargetCyclin-dependent kinase 2/G1/S-specific cyclin-E1(Human)
Gi Therapeutics

US Patent
LigandPNGBDBM253920(US9464092, L | US9527857, L)
Affinity DataIC50: 4.53E+3nMAssay Description:Selected compounds disclosed herein were tested in CDK4/cyclinD1, CDK2/CycA and CDK2/cyclinE kinase assays by Nanosyn (Santa Clara, Calif.) to determ...More data for this Ligand-Target Pair
In Depth
Date in BDB:
12/4/2017
Entry Details
US Patent

TargetCyclin-A1/Cyclin-dependent kinase 2(Human)
Gi Therapeutics

US Patent
LigandPNGBDBM253920(US9464092, L | US9527857, L)
Affinity DataIC50: 1.49E+3nMAssay Description:Selected compounds disclosed herein were tested in CDK4/cyclinD1, CDK2/CycA and CDK2/cyclinE kinase assays by Nanosyn (Santa Clara, Calif.) to determ...More data for this Ligand-Target Pair
In Depth
Date in BDB:
12/4/2017
Entry Details
US Patent